Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.

Abstract

OBJECTIVE:

To evaluate the action of vildagliptin + metformin on some adipocytokine levels, glycemic control, and β-cell function in type 2 diabetic patients.

RESEARCH DESIGN AND METHODS:

A total of 171 patients with poor glycemic control were instructed to add after a 8 ± 2 month-run-in period with metformin, vildagliptin 50 mg twice a day or placebo for 12 months.

MAIN OUTCOME MEASURES:

We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, resistin, retinol-binding protein-4 (RBP-4), chemerin, and tumor necrosis factor-α (TNF-α). Patients also underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion.

RESULTS:

After 12 months of vildagliptin + metformin, we observed a better decrease of body weight, glycemic control, HOMA-IR, and glucagon, and a better increase of HOMA-β, and of all the measures of β-cell function, compared to placebo + metformin. Vildagliptin + metformin also decreased resistin, RBP-4, and chemerin better.

CONCLUSION:

Vildagliptin seems to have a positive action on some adipocytokines related to inflammation.

• Authors: Giuseppe Derosa, Pietro D Ragonesi, Anna Carbone, Elena Fogari, Angela D'Angelo, Arrigo F G Cicero, Pamela Maffioli
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 13 Issue 18 Pg. 2581-91 (12 2012) ISSN: 1744-7666 [Electronic] England
• PMID: 23121473 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Chemokines
• Dipeptidyl-Peptidase IV Inhibitors
• Insulin
• Intercellular Signaling Peptides and Proteins
• Nitriles
• Pyrrolidines
• RARRES2 protein, human
• RBP4 protein, human
• RETN protein, human
• Resistin
• Retinol-Binding Proteins, Plasma
• Metformin
• Vildagliptin
• Adamantane

Topics

• Adamantane (analogs & derivatives, therapeutic use)
• Adult
• Chemokines (blood)
• Diabetes Mellitus, Type 2 (drug therapy, immunology, metabolism, physiopathology)
• Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
• Double-Blind Method
• Down-Regulation (drug effects)
• Drug Therapy, Combination
• Female
• Humans
• Hyperglycemia (prevention & control)
• Insulin (metabolism)
• Insulin Resistance
• Insulin Secretion
• Insulin-Secreting Cells (drug effects, metabolism)
• Intention to Treat Analysis
• Intercellular Signaling Peptides and Proteins
• Male
• Metformin (therapeutic use)
• Middle Aged
• Nitriles (therapeutic use)
• Pyrrolidines (therapeutic use)
• Resistin (blood)
• Retinol-Binding Proteins, Plasma (analysis)
• Vildagliptin